Skip to main content
Log in

Paradoxical sleep deprivatory effect of a single low dose of MPTP which did not produce dopaminergic cell loss

  • Published:
Experimental Brain Research Aims and scope Submit manuscript

Abstract

In a previous study, we reported on a selective and long-lasting paradoxical sleep (PS) deprivation in cats following repeated administration of the Parkinson syndrome-inducing neurotoxin N-methyl-4-pheny11,2,3,6-tetrahydropyridine (MPTP). While the characteistic motor deficits occurred only from the 2nd to 3rdday of a 5-day long administration of 5 mg/kg per day MPTP i.p., the PS deprivation started immediately after the first injection and lasted altogether for 11–13 days. The motor deficiencies induced by repeated administration of MPTP are mainly due to the selective depletion of dopaminergic neurons in the nigrostriatal system as the histological and biochemical data show. The immediate onset of PS deprivation and the PS recovery, despite the definite cell loss, suggests a mechanism independent of cell destruction. In our present study we investigated the occasional histological and the PS-deprivatory effect of a single low dose of MPTP in cats. A single injection of 2 mg/kg MPTP i.p. resulted in PS deprivation lasting for 2.5–3.5 h. The duration of other sleep stages showed no significant change and PS recovery was without rebound phenomenon, as in the case of repeated administration. Even a higher single dose of MPTP (5 mg/kg) resulted in no visibly detectable nigrostriatal cell loss. We suggest that the changes in monoamine release and/or turnover are involved in the PS deprivatory effect of MPTP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Chiba K, Trevor AJ, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 120:574–578

    Google Scholar 

  • Chiueh CC, Markey SP, Burns RS, Johannessen JN, Pert A, Kopin IJ (1984) Neurochemical and behavioral effect of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine in the rat. Eur J Pharmacol 100:189–194

    Google Scholar 

  • Herkenham M, Little MD, Bankiewicz K, Yang SC, Johannessen JN (1991) Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40:133–158

    Google Scholar 

  • Hobson JA, Lydic R, Baghdoyan KA (1986) Evolving concepts of sleep cycle generation: from brain centers to neuronal populations. Behav Brain Sci 9:371–448

    Google Scholar 

  • Irwin I, Langston JW (1985) Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? Life Sci 36:207–212

    Google Scholar 

  • Jawitch JA, Snyder SH (1985) Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism inducing neurotoxin MPTP. Eur J Pharmacol 106:455–456

    Google Scholar 

  • Jones BE (1991) Paradoxical sleep and its structural/chemical substrates in the brain. Neuroscience 40:637–656

    Article  CAS  PubMed  Google Scholar 

  • Kopin IJ (1987) MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new area in research on Parkinson's disease. Environ Health Perspect 75:45–51

    Google Scholar 

  • Langston JW (1985) MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci 36:201–206

    Google Scholar 

  • Langston JW, Irwin I (1986) MPTP: current concepts and controversies. Clin Neuropharmacol 9:485–507

    CAS  Google Scholar 

  • Langston JW, Irwin I, Langston EB, Forno L (1984) 1-methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 214:1370–1372

    Google Scholar 

  • Markey SP, Schmuff NR (1986) The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3–6-tetrahydropyridine) and structurally related compounds. Med Res Rev 6:389–429

    Google Scholar 

  • Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADHlinked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36:2503–2508

    Article  CAS  PubMed  Google Scholar 

  • Poirier J (1987) Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism. J Am Geriatr Soc 35:660–668

    Google Scholar 

  • Pungor K, Papp M, Kékesi K, Juhász G (1990) A novel effect of MPTP: the selective deprivation of paradoxical sleep in cats. Brain Res 525:310–314

    Google Scholar 

  • Schneider JS, Yuwiler A, Markham CH (1986) Production of a Parkins-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology and biochemistry. Exp Neurol 91:293–307

    Google Scholar 

  • Singer TP, Ramsay RR (1990) Mechanism of the neurotoxicity of MPTP. An update. FEBS Lett 274:1–8

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pungor, K., Hajnal, A., Kékesi, K.A. et al. Paradoxical sleep deprivatory effect of a single low dose of MPTP which did not produce dopaminergic cell loss. Exp Brain Res 95, 473–476 (1993). https://doi.org/10.1007/BF00227140

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00227140

Key words

Navigation